Published in AIDS on November 04, 2005
Web resources for HIV type 1 genotypic-resistance test interpretation. Clin Infect Dis (2006) 5.90
HIV-1 drug resistance mutations: an updated framework for the second decade of HAART. AIDS Rev (2008) 2.88
High prevalence of the K65R mutation in human immunodeficiency virus type 1 subtype C isolates from infected patients in Botswana treated with didanosine-based regimens. Antimicrob Agents Chemother (2006) 2.23
HIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programme. Antivir Ther (2009) 2.18
HIV-1 antiretroviral resistance: scientific principles and clinical applications. Drugs (2012) 1.70
Differences in resistance mutations among HIV-1 non-subtype B infections: a systematic review of evidence (1996-2008). J Int AIDS Soc (2009) 1.65
Consensus drug resistance mutations for epidemiological surveillance: basic principles and potential controversies. Antivir Ther (2008) 1.58
HIV-1 subtype distribution and its demographic determinants in newly diagnosed patients in Europe suggest highly compartmentalized epidemics. Retrovirology (2013) 1.30
Differential drug resistance acquisition in HIV-1 of subtypes B and C. PLoS One (2007) 1.23
HIV-1 Genetic Variability and Clinical Implications. ISRN Microbiol (2013) 1.10
Discordances between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors of human immunodeficiency virus are subtype dependent. Antimicrob Agents Chemother (2006) 1.08
Viremia and HIV-1 drug resistance mutations among patients receiving second-line highly active antiretroviral therapy in Chennai, Southern India. Clin Infect Dis (2012) 1.07
HIV Genetic Diversity and Drug Resistance. Viruses (2010) 0.96
Distinct resistance mutation and polymorphism acquisition in HIV-1 protease of subtypes B and F1 from children and adult patients under virological failure. Infect Genet Evol (2008) 0.89
HIV-1 gp120 N-linked glycosylation differs between plasma and leukocyte compartments. Virol J (2008) 0.86
Comparative analysis of drug resistance among B and the most prevalent non-B HIV type 1 subtypes (C, F, and CRF02_AG) in Italy. AIDS Res Hum Retroviruses (2012) 0.86
Mapping protease inhibitor resistance to human immunodeficiency virus type 1 sequence polymorphisms within patients. J Virol (2007) 0.85
Connection subdomain mutations in HIV-1 subtype-C treatment-experienced patients enhance NRTI and NNRTI drug resistance. Virology (2012) 0.82
Viral Genetic Diversity and Polymorphisms in a Cohort of HIV-1-Infected Patients Eligible for Initiation of Antiretroviral Therapy in Abuja, Nigeria. AIDS Res Hum Retroviruses (2015) 0.81
Novel recombinant virus assay for measuring susceptibility of human immunodeficiency virus type 1 group M subtypes to clinically approved drugs. J Clin Microbiol (2009) 0.80
Expression, purification and preliminary X-ray crystallographic studies of the human immunodeficiency virus 1 subtype C protease. Acta Crystallogr Sect F Struct Biol Cryst Commun (2007) 0.80
Estimating the individualized HIV-1 genetic barrier to resistance using a nelfinavir fitness landscape. BMC Bioinformatics (2010) 0.79
Drug resistance mutation profile and accumulation kinetics in human immunodeficiency virus-positive individuals infected with subtypes B and F failing highly active antiretroviral therapy are influenced by different viral codon usage patterns. Antimicrob Agents Chemother (2008) 0.78
Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One (2009) 8.37
An automated genotyping system for analysis of HIV-1 and other microbial sequences. Bioinformatics (2005) 5.60
The molecular population genetics of HIV-1 group O. Genetics (2004) 4.53
Human T-lymphotropic virus 1: recent knowledge about an ancient infection. Lancet Infect Dis (2007) 3.80
Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis (2005) 3.52
Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med (2005) 3.17
Evolutionary and functional analyses of the interaction between the myeloid restriction factor SAMHD1 and the lentiviral Vpx protein. Cell Host Microbe (2012) 2.66
U.S. Human immunodeficiency virus type 1 epidemic: date of origin, population history, and characterization of early strains. J Virol (2003) 2.64
Transmission of drug-resistant HIV-1 is stabilizing in Europe. J Infect Dis (2009) 2.60
Complete genomic sequence of human coronavirus OC43: molecular clock analysis suggests a relatively recent zoonotic coronavirus transmission event. J Virol (2005) 2.35
Tracing the origin and history of the HIV-2 epidemic. Proc Natl Acad Sci U S A (2003) 2.31
A standardized framework for accurate, high-throughput genotyping of recombinant and non-recombinant viral sequences. Nucleic Acids Res (2009) 2.06
A genotypic drug resistance interpretation algorithm that significantly predicts therapy response in HIV-1-infected patients. Antivir Ther (2002) 1.92
Prevalence and correlates of nonadherence to antiretroviral therapy in a population of HIV patients using Medication Event Monitoring System. AIDS Patient Care STDS (2004) 1.75
Recombination confounds the early evolutionary history of human immunodeficiency virus type 1: subtype G is a circulating recombinant form. J Virol (2007) 1.74
Automated subtyping of HIV-1 genetic sequences for clinical and surveillance purposes: performance evaluation of the new REGA version 3 and seven other tools. Infect Genet Evol (2013) 1.69
Genetic variability and molecular evolution of the human respiratory syncytial virus subgroup B attachment G protein. J Virol (2005) 1.60
DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A. PLoS One (2010) 1.59
Tracing the HIV-1 subtype B mobility in Europe: a phylogeographic approach. Retrovirology (2009) 1.58
Phylogenetic surveillance of viral genetic diversity and the evolving molecular epidemiology of human immunodeficiency virus type 1. J Virol (2007) 1.57
Diagnostic value of different adherence measures using electronic monitoring and virologic failure as reference standards. AIDS Patient Care STDS (2008) 1.54
A synthetic HIV-1 Rev inhibitor interfering with the CRM1-mediated nuclear export. Proc Natl Acad Sci U S A (2002) 1.53
Quantifying differences in the tempo of human immunodeficiency virus type 1 subtype evolution. J Virol (2009) 1.49
Relating increasing hantavirus incidences to the changing climate: the mast connection. Int J Health Geogr (2009) 1.48
Molecular evolution and circulation patterns of human respiratory syncytial virus subgroup a: positively selected sites in the attachment g glycoprotein. J Virol (2004) 1.48
The incidence of multidrug and full class resistance in HIV-1 infected patients is decreasing over time (2001-2006) in Portugal. Retrovirology (2008) 1.38
HIV-1 protease and reverse transcriptase mutation patterns responsible for discordances between genotypic drug resistance interpretation algorithms. J Acquir Immune Defic Syndr (2003) 1.38
Hepatitis C virus evolutionary patterns studied through analysis of full-genome sequences. J Mol Evol (2002) 1.38
Molecular footprint of drug-selective pressure in a human immunodeficiency virus transmission chain. J Virol (2005) 1.36
Comparison of HIV-1 genotypic resistance test interpretation systems in predicting virological outcomes over time. PLoS One (2010) 1.33
Use of electronic monitoring induces a 40-day intervention effect in HIV patients. J Acquir Immune Defic Syndr (2006) 1.33
HIV-1 subtype distribution and its demographic determinants in newly diagnosed patients in Europe suggest highly compartmentalized epidemics. Retrovirology (2013) 1.30
The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes. J Acquir Immune Defic Syndr (2006) 1.27
Analysis of the serotype and genotype correlation of VP1 and the 5' noncoding region in an epidemiological survey of the human enterovirus B species. J Clin Microbiol (2004) 1.22
Investigation of expert rule bases, logistic regression, and non-linear machine learning techniques for predicting response to antiretroviral treatment. Antivir Ther (2009) 1.20
Identification in gelada baboons (Theropithecus gelada) of a distinct simian T-cell lymphotropic virus type 3 with a broad range of Western blot reactivity. J Gen Virol (2004) 1.18
Rising prevalence of HIV-1 non-B subtypes in Belgium: 1983-2001. J Acquir Immune Defic Syndr (2004) 1.17
Profile of resistance of human immunodeficiency virus to mannose-specific plant lectins. J Virol (2004) 1.17
Limitations to contact tracing and phylogenetic analysis in establishing HIV type 1 transmission networks in Cuba. AIDS Res Hum Retroviruses (2007) 1.16
Mapping sites of positive selection and amino acid diversification in the HIV genome: an alternative approach to vaccine design? Genetics (2004) 1.15
Assessment of automated genotyping protocols as tools for surveillance of HIV-1 genetic diversity. AIDS (2006) 1.14
Different epidemic potentials of the HIV-1B and C subtypes. J Mol Evol (2005) 1.12
Rare mutations at codon 103 of HIV-1 reverse transcriptase can confer resistance to non-nucleoside reverse transcriptase inhibitors. AIDS (2005) 1.11
A mutation in the 3' region of the human immunodeficiency virus type 1 reverse transcriptase (Y318F) associated with nonnucleoside reverse transcriptase inhibitor resistance. J Virol (2002) 1.11
Tenofovir resistance and resensitization. Antimicrob Agents Chemother (2003) 1.10
A genotypic resistance assay for the detection of drug resistance in the human immunodeficiency virus type 1 envelope gene. J Virol Methods (2005) 1.10
Phylodynamics of the HIV-1 CRF02_AG clade in Cameroon. Infect Genet Evol (2011) 1.10
In vivo characteristics of human immunodeficiency virus type 1 intersubtype recombination: determination of hot spots and correlation with sequence similarity. J Gen Virol (2003) 1.09
Discordances between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors of human immunodeficiency virus are subtype dependent. Antimicrob Agents Chemother (2006) 1.08
Antiretroviral resistance in different HIV-1 subtypes: impact on therapy outcomes and resistance testing interpretation. Curr Opin HIV AIDS (2007) 1.06
env chimeric virus technology for evaluating human immunodeficiency virus susceptibility to entry inhibitors. Antimicrob Agents Chemother (2002) 1.04
No response to first-line tenofovir+lamivudine+efavirenz despite optimization according to baseline resistance testing: impact of resistant minority variants on efficacy of low genetic barrier drugs. J Clin Virol (2007) 1.03
Mosaic genomes of the six major primate lentivirus lineages revealed by phylogenetic analyses. J Virol (2003) 1.03
Phylogeographical footprint of colonial history in the global dispersal of human immunodeficiency virus type 2 group A. J Gen Virol (2011) 1.03
Phylogenetic reconstruction of a known HIV-1 CRF04_cpx transmission network using maximum likelihood and Bayesian methods. J Mol Evol (2004) 1.03
High GUD incidence in the early 20 century created a particularly permissive time window for the origin and initial spread of epidemic HIV strains. PLoS One (2010) 1.03
Complete genome sequence, taxonomic assignment, and comparative analysis of the untranslated regions of the Modoc virus, a flavivirus with no known vector. Virology (2002) 1.02
Phylogeny of primate T lymphotropic virus type 1 (PTLV-1) including various new Asian and African non-human primate strains. Infect Genet Evol (2006) 1.02
Limited cross-border infections in patients newly diagnosed with HIV in Europe. Retrovirology (2013) 1.01
Functional conservation of HIV-1 Gag: implications for rational drug design. Retrovirology (2013) 1.01
A Bayesian statistical analysis of human T-cell lymphotropic virus evolutionary rates. Infect Genet Evol (2004) 1.01
A comparison of HIV-1 drug susceptibility as provided by conventional phenotyping and by a phenotype prediction tool based on viral genotype. J Med Virol (2009) 1.00
Predictive value of HIV-1 genotypic resistance test interpretation algorithms. J Infect Dis (2009) 1.00
Gender differences in HIV disease progression and treatment outcomes among HIV patients one year after starting antiretroviral treatment (ART) in Dar es Salaam, Tanzania. BMC Public Health (2013) 1.00
Early sequential development of infective dermatitis, human T cell lymphotropic virus type 1-associated myelopathy, and adult T cell leukemia/lymphoma. Clin Infect Dis (2008) 0.99
Performance of ViroSeq HIV-1 Genotyping System in routine practice at a Belgian clinical laboratory. J Virol Methods (2004) 0.99
Antiretroviral therapy optimisation without genotype resistance testing: a perspective on treatment history based models. PLoS One (2010) 0.98
Algorithms for the interpretation of HIV-1 genotypic drug resistance information. Antiviral Res (2006) 0.97
Circulation of genetically distinct contemporary human coronavirus OC43 strains. Virology (2005) 0.97
Genotypic drug resistance interpretation algorithms display high levels of discordance when applied to non-B strains from HIV-1 naive and treated patients. FEMS Immunol Med Microbiol (2006) 0.97
Investigation of baseline susceptibility to protease inhibitors in HIV-1 subtypes C, F, G and CRF02_AG. Antivir Ther (2006) 0.97
Molecular testing of multiple HIV-1 transmissions in a criminal case. AIDS (2005) 0.96
The rise and fall of K65R in a Portuguese HIV-1 Drug Resistance database, despite continuously increasing use of tenofovir. Infect Genet Evol (2008) 0.96
HIV-1 compartmentalization in diverse leukocyte populations during antiretroviral therapy. J Leukoc Biol (2004) 0.96
Pharmacy refill adherence outperforms self-reported methods in predicting HIV therapy outcome in resource-limited settings. BMC Public Health (2014) 0.96
Human retroviruses (HIV and HTLV) in Brazilian Indians: seroepidemiological study and molecular epidemiology of HTLV type 2 isolates. AIDS Res Hum Retroviruses (2002) 0.96
APOBEC3G-induced hypermutation of human immunodeficiency virus type-1 is typically a discrete "all or nothing" phenomenon. PLoS Genet (2012) 0.95
Estimating the relative contribution of dNTP pool imbalance and APOBEC3G/3F editing to HIV evolution in vivo. J Comput Biol (2007) 0.95
Genotype and phenotype at baseline and at failure in human immunodeficiency virus-infected antiretroviral-naive patients in a randomized trial comparing zidovudine and lamivudine plus nelfinavir or nevirapine. J Infect Dis (2003) 0.95
Declining prevalence of HIV-1 drug resistance in antiretroviral treatment-exposed individuals in Western Europe. J Infect Dis (2013) 0.94
Bayesian network analyses of resistance pathways against efavirenz and nevirapine. AIDS (2008) 0.94
Comparative performance of the REGA subtyping tool version 2 versus version 1. Infect Genet Evol (2009) 0.94
RegaDB: community-driven data management and analysis for infectious diseases. Bioinformatics (2013) 0.93